Why An Amyloid Positive Test Does Not Mean The Same Disease episode artwork

EPISODE · Jun 11, 2026 · 20 MIN

Why An Amyloid Positive Test Does Not Mean The Same Disease

from The Longevity Podcast: Optimizing HealthSpan & MindSpan · host Dung Trinh

Send us Fan MailA clean diagnosis feels like an X-ray: obvious problem, obvious fix. Alzheimer’s disease is the opposite, and the arrival of disease-modifying anti-amyloid therapies like lecanemab and donanemab makes that gap impossible to ignore. We dig into why real-world patients do not look like “pristine” clinical trial participants, and why a simple amyloid positive label can hide wildly different biology, risks, and likely outcomes.We explore what happens when amyloid burden is patchy or borderline, how centiloid scores and CSF biomarkers (especially the amyloid beta 42 to 40 ratio) create a probabilistic gray zone, and why cognitive decline often reflects more than plaques alone. Cerebrovascular disease and white matter injury can team up with modest amyloid to push a brain over the edge, which changes what “treating the cause” even means.Then we follow the fire inward to tau. Tau tangles disrupt neurons from the inside, and tau PET with Braak staging can reveal severe pathology even when someone still functions well, thanks to cognitive reserve. From there, we zoom out to the ATNIVS framework: Amyloid, Tau, Neurodegeneration, Inflammation, Vascular pathology, and Synuclein. We connect blood biomarkers like plasma NFL and GFAP to active neurodegeneration and neuroinflammation, and we explain why ARIA (amyloid-related imaging abnormalities) risk rises when fragile vessels, inflammation, and cerebral amyloid angiopathy collide with plaque-clearing antibodies.Finally, we cover a provocative twist: seed amplification assays detecting hidden alpha-synuclein in a meaningful share of patients diagnosed with Alzheimer’s, pointing to copathology that can change prognosis and potentially mask drug benefit. If you care about Alzheimer’s biomarkers, precision neurology, and the future of combination therapies, listen through to the end, then subscribe, share the episode, and leave a review with your biggest takeaway.This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

Episode metadata supplied by the publisher feed · Published Jun 11, 2026

Embed this episode

Send us Fan Mail A clean diagnosis feels like an X-ray: obvious problem, obvious fix. Alzheimer’s disease is the opposite, and the arrival of disease-modifying anti-amyloid therapies like lecanemab and donanemab makes that gap impossible to ignore. We dig into why real-world patients do not look like “pristine” clinical trial participants, and why a simple amyloid positive label can hide wildly different biology, risks, and likely outcomes. We explore what happens when amyloid burden is patc...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Why An Amyloid Positive Test Does Not Mean The Same Disease

0:00 20:14

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Longevity Podcast: Optimizing HealthSpan & MindSpan?

This episode is 20 minutes long.

When was this The Longevity Podcast: Optimizing HealthSpan & MindSpan episode published?

This episode was published on June 11, 2026.

Can I download this The Longevity Podcast: Optimizing HealthSpan & MindSpan episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!